Blood component therapy in trauma
Background: Injury is the leading cause of life years lost, and hemorrhage is responsible for 40% of all trauma deaths and is commonly associated with coagulopathy, necessitating the use of blood and blood components. With logistical issues and concerns regarding safety of fresh whole blood because...
Main Authors: | Ambuja Kantharaj, Shivaram Chandrashekar |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
Series: | Global Journal of Transfusion Medicine |
Subjects: | |
Online Access: | http://www.gjtmonline.com/article.asp?issn=2468-8398;year=2016;volume=1;issue=2;spage=66;epage=68;aulast=Kantharaj |
Similar Items
-
Four-factor prothrombin complex concentrate to reduce allogenic blood product transfusion in patients with major trauma, the PROCOAG trial: study protocol for a randomized multicenter double-blind superiority study
by: Pierre Bouzat, et al.
Published: (2021-09-01) -
Blood component therapy: Which, when and how much
by: Rajesh Chand Arya, et al.
Published: (2011-01-01) -
Risk mitigation in blood transfusion services – A practical approach at the blood center level
by: Shivaram Chandrashekar, et al.
Published: (2019-01-01) -
Massive Blood Transfusions and Outcomes in Trauma Patients; An Intention to Treat Analysis
by: Steven Liu, et al.
Published: (2018-07-01) -
High Interleukin-6 Plasma Concentration upon Admission Is Predictive of Massive Transfusion in Severely Injured Patients
by: Nadja Weichselbaum, et al.
Published: (2021-05-01)